We addressed the unmet clinical need of the therapeutic management of patients with brain metastasis from renal cell carcinoma. We retrospectively analyzed 12 patients with brain metastasis treated with cabozantinib from a real-world experience. Cabozantinib was safe and showed promising antitumor activity after an antiangiogenic first-line therapy. Longer survivals were recorded with the integration of brain-directed therapy.
Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population / Peverelli, G.; Raimondi, A.; Ratta, R.; Verzoni, E.; Bregni, M.; Cortesi, E.; Carteni, G.; Fornarini, G.; Facchini, G.; Buti, S.; Galli, L.; Tucci, M.; Prisciandaro, M.; Procopio, G.. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - 17:4(2019), pp. 291-298. [10.1016/j.clgc.2019.05.002]
Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population
Cortesi E.;Facchini G.;
2019
Abstract
We addressed the unmet clinical need of the therapeutic management of patients with brain metastasis from renal cell carcinoma. We retrospectively analyzed 12 patients with brain metastasis treated with cabozantinib from a real-world experience. Cabozantinib was safe and showed promising antitumor activity after an antiangiogenic first-line therapy. Longer survivals were recorded with the integration of brain-directed therapy.| File | Dimensione | Formato | |
|---|---|---|---|
|
Peverelli_Cabozantinib_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
301.42 kB
Formato
Adobe PDF
|
301.42 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
